Results 151 to 160 of about 760,147 (214)

The Impact of US Food and Drug Administration's Advisory and Enforcement Actions on US Sales of Esco Bars Products in 2023: Synthetic Control Approach.

JMIR Public Health Surveill
Shin H, Hannings J, Cahn Z, Xu X, Toblin R, Farrelly M, King BA.   +6 more
europepmc   +1 more source

Transformer-Based Topic Modeling: Characterizing Cannabis Product Adverse Experiences Self-Reported as Requiring Medical Attention on Reddit.

J Med Internet Res
Mackey TK, Nali MC, Larsen MZ, Li Z, Taylor CL, Wolpert B, Trice C.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

United States Food and Drug Administration Drug Approval Summary

Clinical Cancer Research, 2004
Abstract On May 5, 2003, gefitinib (Iressa; ZD1839) 250-mg tablets (AstraZeneca Inc.) received accelerated approval by the United States Food and Drug Administration as monotherapy for patients with locally advanced or metastatic non-small cell lung cancer after failure of both platinum-based and docetaxel chemotherapies.
Martin H. Cohen, Grant A. Williams, Rajeshwari Sridhara, Gang Chen, W. David McGuinn, David Morse, Sophia Abraham, Atiqur Rahman, Chenyi Liang, Richard Lostritto, Amy Baird, Richard Pazdur   +11 more
openaire   +2 more sources

Oncology drug development: United States Food and Drug Administration perspective

Critical Reviews in Oncology/Hematology, 2002
The Food and Drug Administration (FDA) in the United States has multiple roles. The primary responsibilities for oncology drug products are the supervision of clinical research, the evaluation of marketing claims for new and previously approved drugs, the granting of exclusive marketing licenses for approved claims, and the monitoring of post-marketing
Steven, Hirschfeld, Richard, Pazdur
openaire   +2 more sources

End Points and United States Food and Drug Administration Approval of Oncology Drugs

Journal of Clinical Oncology, 2003
Purpose: To summarize the end points used by the United States Food and Drug Administration (FDA) to approve new cancer drug applications over the last 13 years. Materials and Methods: The FDA granted marketing approval to 71 oncology drug applications between January 1, 1990, and November 1, 2002.
John R, Johnson, Grant, Williams, Richard, Pazdur   +2 more
openaire   +2 more sources